Compare NPCE & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPCE | INDP |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.2M | 438.4M |
| IPO Year | 2021 | 2021 |
| Metric | NPCE | INDP |
|---|---|---|
| Price | $7.95 | $3.45 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $14.11 | N/A |
| AVG Volume (30 Days) | ★ 376.2K | 223.3K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,986,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.13 | N/A |
| 52 Week Low | $5.46 | $0.92 |
| 52 Week High | $19.60 | $5.96 |
| Indicator | NPCE | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 23.99 | 57.88 |
| Support Level | N/A | $2.17 |
| Resistance Level | $14.90 | $3.71 |
| Average True Range (ATR) | 0.85 | 0.33 |
| MACD | -0.47 | -0.01 |
| Stochastic Oscillator | 28.83 | 86.81 |
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.